Prevalence and predictors of latent tuberculosis infection among people living with HIV in a high tuberculosis burden context

Lilian N. Njagi[1,2 *], Videlis Nduba[1], Marianne Mureithi[2], Jared O. Mecha[3]

[1] *Centre for Respiratory Disease Research, Kenya Medical Research Institute, Nairobi, Kenya.*

[2] *Department of Medical Microbiology & Immunology, Faculty of Health Sciences, University of Nairobi, Kenya.*

[3] *Department of Clinical Medicine and Therapeutics, Faculty of Health Sciences, University of Nairobi School of Medicine, Kenya.*

[*]***Corresponding author:*** *e-mail: njagi.lilian@gmail.com, Tel +254722575686, postal address 2335-00202 Nairobi, Kenya.*

Word count: 2659

ABSTRACT

Background: Tuberculosis (TB) is the leading cause of mortality among people living with the Human immunodeficiency virus (PLHIV), and latent TB infection (LTBI) contributes significantly to active TB. Direct diagnostic methods are the most accurate tests for establishing the LTBI burden. However, current interferon-gamma release assay (IGRA) data on LTBI prevalence in the context of near-universal access to antiretroviral therapy (ART) and widespread TB preventive therapy (TPT) implementation are lacking. We estimated the prevalence and determinants of LTBI among PLHIV within a high TB and HIV burden context. **Methods:** This cross-sectional analysis of a prospectively collected observational study data included adult PLHIV, in whom QuantiFERON-TB Gold Plus assay, an IGRA, was performed. LTBI was defined as a positive or indeterminate IGRA. Participants with TB and those who had used TB preventive therapy in the past were excluded. Regression analysis was performed to identify independent predictors of LTBI. **Results** Of 121 PLHIV with IGRA results, females were 74.4% (90/121), and the mean age was 38.4 (standard deviation [SD] 10.8) years. Overall, 47.9% (58/121) were classified as LTBI (IGRA positive and indeterminate results were 39.7% [48/121] and 8.3% [10/121], respectively), with mean ages of 38.7 (SD 10.30) vs 38.2 (SD 11.3) years, respectively (p=0.602). Being obese/overweight (body mass index ≥25; p=0.046, adjusted odds ratio (aOR) 2.65, 95% confidence interval [CI] 1.02–6.89), alcohol usage (p=0.036, aOR 3.93, 95% CI 1.10–14.13), and ART usage for >3 years (p=0.012, aOR 2.65, 95% CI 1.23–5.69) were independently associated with LTBI. **Conclusion:** There was a high LTBI prevalence among PLHIV. A longer period of ART and alcohol consumption were independently associated with LTBI. The relationship between obesity/overweight and LTBI may be related to ART and immune reconstitution and requires further investigation. Recommending IGRA to ascertain LTBI status in PLHIV previously unexposed to TPT may be necessary.

Keywords: Immunodeficiency, HIV; Africa; Interferon-gamma release assay; Prevalence; Latent tuberculosis infection (LTBI)

KEY MESSAGES

What is already known on this topic

Among people living with HIV (PLHIV), the risk of progression to active tuberculosis (TB) is higher with confirmed and untreated latent TB infection (LTBI). Data on the prevalence of LTBI in the context of near-universal access to antiretroviral therapy (ART) and widespread TB preventive therapy (TPT) implementation in Africa are lacking.

What this study adds

This study provides evidence that the prevalence of LTBI remains high even in the contest of near-universal ART and widespread TPT. ART use, alcohol consumption, and obesity/overweight may be associated with LTBI.

How this study might affect research, practice or policy

Recommending IGRA to ascertain LTBI status in PLHIV previously unexposed to TPT may be necessary. This study should prompt larger studies to explore predictors of LTBI and the role of confirming LTBI before tuberculosis preventive therapy.

INTRODUCTION

Tuberculosis (TB) continues to be a global health concern.(1-4) Despite near-universal access to antiretroviral therapy (ART), TB remains the leading cause of disease and mortality among people living with HIV (PLHIV).(3-5) In 2020, as in 2019, approximately 10 million people developed TB worldwide, 8% of whom were PLHIV.(3, 4) In the same period, though deaths from HIV/AIDS decreased, deaths from TB among PLHIV increased.(4) Kenya is among the thirty high TB burden countries. In 2019, the country had 140 000 incident TB cases, and 26% (37 000) were HIV/TB co-infected, of whom 35% (13 000) died.(3) This trend continued in 2020.(4) Reactivated latent TB infection (LTBI) contributes significantly to the incidence of TB.(6, 7) The global burden of LTBI is estimated at a quarter of the population,(8) with wide regional variation.(9, 10)

Current information on the burden of LTBI in Africa and among PLHIV is sparse.(9, 10) There are also limited data on how the prevalence of LTBI has changed with near-universal access to ART and the widespread implementation of TB preventive therapy (TPT). Other factors associated with LTBI among PLHIV are underexplored.(11-13) Establishing the actual burden of LTBI and the associated risk factors in PLHIV is important for various reasons. First, the risk of progression from latent to active TB is higher among PLHIV with a positive test for LTBI than among those with a negative or unknown test result.(14) Second, TB risk is markedly reduced by TPT, with a 64% risk reduction among PLHIV with a positive test, compared to 14% among those with a negative or unknown test.(15) Finally, this information has potential implications for practice.(16)

Direct diagnostic methods are the most accurate for establishing the LTBI burden. This paper presents the results of a study which sought to estimate the prevalence of LTBI infection among PLHIV using interferon-gamma release assay (IGRA) in a high TB burden context. Further, the determinants of LTBI in this population were explored.

METHODS

Study setting and design

This cross-sectional study used all data from a prospective observational study conducted at HIV care and prevention centres at two referral hospitals and one research institution in Nairobi, Kenya.

Study period and population

Participants seeking HIV care and prevention services from the three facilities between December 2019 and December 2020 were eligible to participate in the study. All study participants underwent the recommended four TB symptom screening questions and had physical examinations to rule out active TB infection. Participants suspected of having active TB and those who had received isoniazid for LTBI were excluded. Of the 244 participants who consented to participate in the prospective observational study, 121 that were HIV-infected were selected for the study.

Variables and definitions

The outcome variable of interest was the LTBI status. LTBI was defined as a positive or indeterminate IGRA result. We included indeterminate results in the definition of LTBI for several reasons. The foremost was the clinical implication based on the existing WHO and country recommendations to treat all PLHIV for LTBI without a confirmatory test. Routine testing for LTBI is not recommended in Kenya. Second, repeat testing for indeterminate results was impossible as resources were limited, and most results would have remained indeterminate on repeat testing based on the manufacturer's instructions. All participants with negative results were considered to have no LTBI. The explanatory variables of interest were age, sex, body mass index (BMI) calculated from weight and height, smoking habit as ever smoked, alcohol use as more than social drinking, living conditions as crowded or not, known contact with a known TB case in the preceding two years, diabetes status, duration on ART in months, and viral load level as HIV copies per millilitre of blood.

Clinical and laboratory procedures

At baseline, clinical and demographic data were collected or abstracted from electronic medical records. These included age sex, weight, height, smoking status, alcohol use, living conditions, diabetes status,

history of TB infection and isoniazid use. HIV rapid testing was performed in programmatic settings for those of unknown status, as part of HIV prevention. Where feasible, a CD4 lymphocyte count was performed. Viral load was performed for all participants on ART for at least 6 months according to national guidelines. The ART initiation date was collected to determine the duration of antiretroviral drugs. Viral load test and ART duration were used as a proxy for immune reconstitution and competency in the absence of CD4 lymphocyte count.

We used the QuantiFERON-TB Gold Plus (QFT-Plus) assay for LTBI diagnosis according to the manufacturer's protocol.

Statistical analysis

After appropriate data cleaning, the analysis was performed using Stata Statistical Software version 17 (StataCorp LP, College Station, TX, USA). Descriptive statistics were used to summarise the sociodemographic and clinical characteristics of the participants. Pearson's chi-square and Fisher's exact tests were used to test the association between categorical variables and outcomes, and the odds ratios were reported. For continuous variables, the Student's t-test was used. On univariate analysis, factors with a p-value < 0.25 were included in the multivariate logistic regression analyses. Statistical significance was set at $p < 0.05$. Missing data were addressed by removal to reduce bias.

Patient and public involvement

It was not possible to involve patients or the public in the design, conduct, reporting, or dissemination plans of our research. Patients were involved to the extent to which they provided informed consent and allowed for sample collection for laboratory testing. The study results will be communicated to willing participants and community members.

Ethical considerations

This study was approved by the Kenyatta National Hospital and University of Nairobi Institutional Review Board. Written informed consent were obtained from all participants enrolled in the study.

RESULTS

Socio-demographic and clinical characteristics of participants

Among the 121 study participants living with HIV included in this analysis, females were the majority at 74.4% (90/121). The mean age of all participants was 38.4 years with a standard deviation (SD) of 10.8, and 51% (62/121) of the participants were ≥40 years. By BMI, 46% (56/121) of the participants were categorised as overweight or obese, and 4% (5/121) as underweight. Among the social risk factors, 18.3% (22/121) were cigarette smokers, 20.7% (25/121) used alcohol, 27.3% (33/121) reported living in a crowded place, and 26.4% (32/121) had known contact with TB cases. Regarding clinical and laboratory characteristics, only 2.5% (3/121) had diabetes, and 38% (n=118) had been on ART for >3 years. The median duration on ART was 3.9 years among the 118 participants with a documented ART start date. The virally suppressed participants, using a cut-off value of 40 copies per ml, were 85.7% (102 of 119 with viral load results). **Table 1** shows the participants' sociodemographic and clinical characteristics.

Prevalence of LTBI estimated by IGRA results

The prevalence of LTBI estimated by IGRA results in this population of PLHIV was 47.9% (58/121; Table 1). This comprised 39.7% (48/121) with a positive IGRA report and 8.3% (10/121) with an indeterminate IGRA report. Among the participants with indeterminate results, six were female, and none of the patients had an underlying chronic illness other than HIV. In eight of the 10 cases with indeterminate results, the interferon-gamma (IFN-γ) level in response to mitogen was <0.5 IU/mL. Given the low mitogen response, repeated testing would have yielded indeterminate results. In three of the 10 cases with indeterminate results, the IFN-γ response in the Nil tube was >8.0 IU/mL signifying an ongoing immune response. These results justify the operational definition of LTBI used in the present study.

Determinants of LTBI estimated by IGRA results

The mean age of participants with LTBI was 38.7 years (standard deviation [SD] 10.3) compared to 38.2 years (SD 11.3) among those without LTBI (p=0.6022) (Table 2). BMI (p=0.027, crude odds ratio

[cOR] 2.31, 95% confidence interval [CI] 1.10–4.86), smoking status (*p*=0.010, cOR 3.62, 95% CI 1.31–10.03), and duration of ART use in years (*p*=0.004, cOR 3.99, 95% CI 1.55–10.28) were significantly associated with LTBI defined as positive or indeterminate IGRA results (Table 2). On multivariate analysis (Table 3), being obese/overweight (BMI ≥25; p=0.046, adjusted odds ratio (aOR) 2.65, 95% CI 1.02–6.89), using alcohol (*p*=0.036, aOR 3.93, 95% CI 1.10–14.13), and being on ART for >3 years (*p*=0.012, aOR 2.65, 95% CI 1.23–5.69) were independently associated with LTBI. Increased odds of having LTBI was observed among females (aOR 1.08, 95% CI 0.39–2.98), those aged >40 years (aOR 1.22, 95% CI 0.36–4.14), those with history of smoking cigarettes (aOR 2.58, 95% CI 0.51–13.11), those with history of contact with a case of TB (aOR 2.032, 95% CI 0.60–6.93), and those having a viral load of >40 copies/ml (aOR 1.20, 95% CI 0.34–4.29). However, these findings were not statistically significant (**table 3**).

Table 1 Socio-demographic and clinical characteristics of participants (n 121)

Variable	**Frequency (N = 121)**	**No LTBI [1] (n = 63)**	**LTBI[2] (n = 58)**
Demographic variables			
Gender (n, %)			
Female	90	47 (52.2)	43 (47.8)
Male	31	16 (51.61)	15 (48.4)
Age (mean, SD)	38.4, 10.8	(38.2, 11.3)	(38.7, 10.3)
Age groups (n, %)			
< 30	26	15 (57.7)	11 (42.3)
30–39	33	19 (57.6)	14 (42.4)
≥ 40	62	29 (46.8)	33 (53.2)
BMI (n, %)			
< 18.5	5	3 (60.0)	2 (40.0)
18.5–< 25.0	60	37 (61.7)	23 (38.3)
25.0–30.0	37	12 (32.4)	25 (67.6)
≥ 30	19	11 (57.9)	8 (42.1)
Social risk factors			
History of smoking (n, %)			
No	99	57 (57.6)	42 (42.4)
Yes	22	6 (27.3)	16 (72.7)
Alcohol use (n, %)			
No	96	54 (56.3)	42 (43.8)
Yes	25	9 (36.0)	16 (64.0)
Living conditions (n, %)			
Not crowded	88	47 (53.4)	41 (46.6)
Crowded	33	16 (48.5)	17 (51.5)
History of contact with TB case (n, %)			
No	89	51 (57.3)	38 (42.7)
Yes	32	12 (37.5)	20 (62.5)

Clinical and laboratory characteristics			
Diabetes status (n, %) No Yes	 118 3	 60 (50.9) 3 (100.0)	 58 (49.2) 0 (0.0)
Duration on ART in years (n, %) [3] ≤ 3 > 3	 73 45	 45 (61.6) 17 (37.8)	 28 (38.4) 28 (62.2)
Viral load level (copies/ml; n, %) [4] < 40 > 40	 102 (85.7) 17 (14.3)	 52 (51.0) 9 (52.9)	 50 (49.0) 8 (47.1)
[1]Negative IGRA; [2] Positive & indeterminate IGRA; [3] n = 118, 3 participants did not have a documented ART start date; [4] n = 119, 2 participants did not have a valid viral load report			

Table 2 Determinants of LTBI among PLHIV – bivariate analysis (N 121)

Variable	No LTBI[1] (n = 63)	LTBI[2] (n = 48)	P-value	Pearson chi2
Baseline characteristics				
Gender (n, %) Male Female	 16 (51.61) 47 (52.2)	 15 (48.4) 43 (47.8)	 0.953	 0.0034
Age (mean, SD)	(38.2, 11.3)	(38.7, 10.3)	0.602	-
Age groups (n, %) < 30 30–39 > 40	 15 (57.7) 19 (57.6) 29 (46.8)	 11 (42.3) 14 (42.4) 33 (53.2)	 0.490	 1.4268
BMI (n, %) 18.5–< 25 ≥ 25.0	 37 (61.7) 23 (41.1)	 23 (38.3) 33 (58.9)	 **0.027**	 4.9203
Social risk factors				
History of smoking (n, %) No Yes	 57 (57.6) 6 (27.3)	 42 (42.4) 16 (72.7)	 **0.010**	 6.6229
Alcohol use (n, %) No Yes	 54 (56.3) 9 (36.0)	 42 (43.8) 16 (64.0)	 **0.071**	 3.2590
Living conditions (n, %) Not crowded Crowded	 47 (53.4) 16 (48.5)	 41 (46.6) 17 (51.5)	 0.629	 0.2332
Contact with TB[3] case (n, %) No Yes	 51 (57.3) 12 (37.5)	 38 (42.7) 20 (62.5)	 **0.054**	 3.6986
Clinical and laboratory characteristics				
Diabetes status (n, %) No Yes	 60 (50.9) 3 (100.0)	 58 (49.2) 0 (0.0)	 0.092	 2.8321
Duration on ART in years (n, %)[4] ≤ 3 > 3	 45 (61.6) 17 (37.8)	 28 (38.4) 28 (62.2)	 **0.012**	 6.3591

Viral load level (copies/ml; n, %)[5]				
< 40	52 (50.98)	50 (49.0)		
> 40	9 (52.9)	8 (47.1)	0.881	0.0224
[1]Negative IGRA; [2] Positive & indeterminate IGRA; [3]Tuberculosis; [4] n = 118, 3 participants did not have a documented antiretroviral therapy (ART) start date; [5] n = 119, 2 participants did not have a valid viral load report				

Table 3 Logistic regression analysis for factors associated with LTBI (N=121)

Variable	No LTBI[1] (n = 63)	LTBI[2] (n = 48)	P-value	cOR[3] (95% CI.)	aOR[4] (95% CI.)
Baseline characteristics					
Gender (n, %)					
Male	16 (51.61)	15 (48.4)	Ref	Ref	Ref
Female	47 (52.2)	43 (47.8)	0.888	0 .98 (0.43–2.21)	1.08 (0.39–2.98)
Age (mean, SD)	(38.2, 11.3)	(38.7, 10.3)		-	-
Age groups (n, %)					
< 30	15 (57.7)	11 (42.3)	Ref	Ref	Ref
30–39	19 (57.6)	14 (42.4)	0.687	1.00 (0.36–2.84)	0.77 (0.21–2.81)
> 40	29 (46.8)	33 (53.2)	0.751	1.55 (0.62–3.91)	1.22 (0.36–4.14)
BMI (n, %)					
18.5–< 25	37 (61.7)	23 (38.3)		Ref	Ref
≥ 25.0	23 (41.1)	33 (58.9)	0.046	2.31 (1.10–4.86)	2.65 (1.02–6.89)
Social risk factors					
History of smoking (n, %)					
No	57 (57.6)	42 (42.4)		Ref	Ref
Yes	6 (27.3)	16 (72.7)	0.253	3.62 (1.31–10.03)	2.58 (0.51–13.11)
Alcohol use (n, %)					
No	54 (56.3)	42 (43.8)	0.036	Ref	Ref
Yes	9 (36.0)	16 (64.0)		2.29 (0.092–5.68)	3.93 (1.10–14.13)
Living conditions (n, %)					
Not crowded	47 (53.4)	41 (46.6)	Ref	Ref	Ref
Crowded	16 (48.5)	17 (51.5)	0.079	1.22 (0.55–2.71)	0.33 (0.10–1.13)
Contact with TB[5] case (n, %)					
No	51 (57.3)	38 (42.7)	Ref	Ref	Ref
Yes	12 (37.5)	20 (62.5)	0.257	2.24 (0.98–5.13)	2.03 (0.60–6.93)
Clinical and laboratory characteristics					
Duration on ART in years (n, %)[6]					
≤ 3	45 (61.6)	28 (38.4)	Ref	Ref	Ref
> 3	17 (37.8)	28 (62.2)	0.004	2.65 (1.23–5.69)	3.99 (1.55–10.28)
Viral load level (copies/ml; n, %)[7]					
< 40	52 (50.98)	50 (49.0)	Ref	Ref	Ref
> 40	9 (52.9)	8 (47.1)	0.778	0.92 (0.33–2.59)	1.20 (0.34–4.29)
[1]Negative IGRA; [2]Positive & indeterminate IGRA; [3]crude odds ratio; [4]adjusted odds ratio; [5]Tuberculosis; [6]n = 118, 3 participants did not have a documented antiretroviral therapy (ART) start date; [7] n = 119, 2 participants did not have a valid viral load report					

DISCUSSION

We used the IGRA to estimate the prevalence and determinants of LTBI among PLHIV in the context of a high TB/HIV burden, near-universal ART access, and widespread TPT implementation. We found that the IGRA positivity in this population of PLHIV was 39.7%. This rate corresponds to estimates from the general population in an equivalent context.(17) This differs slightly from a similar study conducted among pregnant women in Kenya, where 35.8% of the pregnant women living with HIV had LTBI by IGRA positivity rate equivalent to those without HIV.(18) In Nigeria, in a similar high HIV/TB burden setup, Aladesanmi et al. found that 53% of PLHIV had LTBI (19). Globally, LTBI is estimated at 25% of the world population.(1, 2) This variability, both geographically and by population, underscores the need for regular context-specific determination of the prevalence of LTBI. The current WHO and local guidelines indicate that the confirmation of LTBI by testing is not a prerequisite for TPT.(20) The most significant benefit following TPT is among PLHIV with laboratory-confirmed LTBI.(15) Therefore, it is essential to consider the cost versus benefit implications of treating individuals who do not need treatment. From our findings, the current policy results in 60% of PLHIV receiving unnecessary TPT, potentially exposing them to avoidable adverse drug events, drug-drug interactions, polypharmacy, and increased risk of non-adherence.

We found that indeterminate results were reported in 8.3% of the cases, a rate similar to that of the general population but lower than those reported among PLHIV.(21-23) An altered immune response increases the likelihood of indeterminate results.(11, 21, 22, 24-26) HIV can lead to indeterminate results even with immune reconstitution due to altered T-cell function,(27-29) and a low CD4 cell count is often implicated.(23, 30, 31) The rate of indeterminate result findings comparable to that of the average population in our study can be explained in two ways. First, although CD4 counts were unavailable, most participants-initiated ART early in the ‘Test and Treat’ era. We speculated that they had competent immunity.(32) Second, most participants had been on ART long enough (median duration on ART being 3.9 years) and had achieved and sustained viral suppression. ART duration influences immune recovery.(32-35)

Indeterminate IGRA results are usually due to either a decrease in IFN-γ production in the mitogen tube or an increase in the Nil tube. In our study, we found decreased production of IFN-γ in the mitogen tube in 8 out of 10 cases. IFN-γ is typically produced by T lymphocytes. In the absence of other factors to explain this, it is possible that T lymphocytes were compromised in quality and were thus unable to produce IFN-γ. In cases of decreased IFN-γ production in the mitogen tube, repeat testing is counterproductive. The increase in the Nil tube >8.0 IU/mL found in three of the 10 cases signifies an ongoing immune response, and LTBI cannot be ruled out. Interpreting indeterminate results is a clinical dilemma when testing before TPT is recommended. The WHO policy does not require testing for LTBI before initiating TPT. For this reason, indeterminate results were included in the definition of LTBI in this study, bringing the proportion of PLHIV classified as having LTBI to 47.9%.

LTBI was significantly higher among participants who were obese/overweight (BMI ≥25), who were using alcohol, and who had been on ART for >3 years. The association with obesity differed from previous findings, although PLHIV were not explicitly considered in these studies.(36-38) Obesity is associated with an increased risk of diabetes,(38) which increases the risk of LTBI and progression to active TB.(39, 40) Additionally, ART is implicated in various components of metabolic syndrome, including an increased risk of hyperglycaemia and diabetes.[41] However, our study only assessed self-reported diabetes and did not measure the haemoglobin A1c (HbA1c) level to determine its association with LTBI. We hypothesised that being on ART for >3 years resulted in CD4 recovery to at least the lower end of the normal range with increased yield from IGRA testing.(31) Alcohol use has been shown to increase the likelihood of LTBI (41) and TB,(42) which supports our findings. The cause could be multifactorial. Structurally, people who consume alcohol are more likely to congregate in crowded places with high TB transmission rates. Alcohol is also known to cause immune suppression, which increases the risk of infection.(43) There was no association between LTBI and age,(12, 44, 45) living in a crowded place, or contact with a person with TB compared to findings from other studies.(17) This could be due to the small sample size and the reduced power required to detect an association.

STUDY STRENGTHS AND LIMITATIONS

Our study had several strengths. The involvement of participants visiting the national referral hospital, who were a cosmopolitan group, increased the ability to generalise our findings. We excluded participants with prior exposure to TPT, thus reducing the chance of outcome misclassification. A limitation of our study is that we did not collect data on CD4 counts and could not account for the association of immune status with LTBI. This was due to changes in the guidelines, precluding the use of CD4 for HIV monitoring. To address this, we used years of ART and viral load measurements as proxies for immune recovery and competency. Second, alcohol and cigarette use levels were based on self-reporting, which is subject to error and social desirability bias. Third, obesity was assessed and not correlated with other metabolic dysfunctions, and diabetes status was not objectively ascertained. Finally, a larger sample size would have had more power to detect associations. Therefore, studies with larger sample sizes are necessary to better elucidate the factors affecting indeterminate IGRAs.

CONCLUSION AND RECOMMENDATION

The prevalence of LTBI in this population of PLHIV who had not received TPT is higher than the global estimate, depicting high levels of exposure and better performance of IGRA with early and longer ART use. The rates of indeterminate results were the same as those reported for the general population, further supporting the effect of ART on immunity and IGRA sensitivity. It may be necessary to recommend using IGRA to ascertain the LTBI status in PLHIV never exposed to TPT. Given the superior benefit of TPT among PLHIV confirmed to have LTBI, a policy change should be considered that requires testing for LTBI before TPT. A re-evaluation of the cost-benefit analysis based on the burden of infection may be helpful. People with vulnerabilities, such as obesity and alcoholism, need to be targeted for TPT. A more in-depth analysis of the determinants of LTBI using a larger sample size is recommended.

ABBREVIATIONS

ART, antiretroviral therapy; CD4, cluster of differentiation 4; CI, confidence interval; HIV, human immunodeficiency virus; IGRA, interferon-gamma release assay; LTBI, latent tuberculosis infection;

PLHIV, people living with human immunodeficiency virus; SD, standard deviation; TB, tuberculosis; TPT, tuberculosis preventive therapy; WHO, World Health Organization

DECLARATIONS

Ethics approval and consent to participate: This study was approved by the Kenyatta National Hospital/University of Nairobi Institutional Review Board (KNH/UON ERB) under Ref. KNH-ERC/A/375.

Consent for publication: No individual personal data are included in this manuscript. All data were anonymised and extracted after obtaining informed consent and ethical approval to conduct the study.

Availability of data and materials: All data generated or analysed during this study are not publicly available due to privacy policy regulations but are available from the corresponding author upon reasonable request.

Competing interests: The authors declare that they have no competing financial or nonfinancial interests.

Funding: This work was supported by funding from the Consortium for Advanced Research Training in Africa (CARTA), the Royal Society of Tropical Medicine and Hygiene (RSTMH), and World Bank through the Materials, Products, and Nano Technology (MAPRONANO) project. The funders had no role in study design, data collection and analysis, publication decisions, or manuscript preparation.

Author contributions: Concept development and study design: LNN, JOM, VN. Supervision of the Study: LNN, JOM, VN, and MM. Data analysis: LNN and VN. Critically revised manuscript: LNN, JOM, VN, and MM. All authors have read and approved the final draft for publication.

Acknowledgements: The LNN was supported by CARTA. CARTA is jointly led by the African Population and Health Research Centre and the University of the Witwatersrand and funded by the Carnegie Corporation of New York (Grant No. G-19–57145), Sida (Grant No:54100113), Uppsala Monitoring Centre, Norwegian Agency for Development Cooperation (Norad), the Wellcome Trust (reference no. 107768/Z/15/Z), and the UK Foreign, Commonwealth & Development Office, with support from the Developing Excellence in Leadership, Training and Science in Africa (DELTAS

Africa) programme. The statements made and views expressed are solely the responsibility of the Fellow. For open access, the authors have applied a CC BY public copyright licence to any Author Accepted Manuscript version arising from this submission.

We thank the patients who volunteered for this study and the research team involved in data collection. We also thank the staff and administration of the Kenyatta National Hospital's comprehensive care clinic and Pumwani Maternity Hospital for supporting this work. We would also like to acknowledge the University of Nairobi, Faculty of Health Sciences, for doctoral training support and the TB HIV Training Program for the training support provided during manuscript development.

We would like to thank Editage (www.editage.com) for English language editing

Authors' information: Lilian N. Njagi: MBChB, MSc, DTMH, PhD and Epi fellow[1,2*]; Videlis Nduba: MBChB, MPH, PhD[1]; Marianne Mureithi: BSc, MSc, PhD[2]; Jared O. Mecha, MBChB, MMEd, MSc, MPH, FCR[3]

[1]Centre for Respiratory Disease Research, Kenya Medical Research Institute, Nairobi, Kenya. [2]Department of Medical Microbiology & Immunology, Faculty of Health Sciences, University of Nairobi, Kenya. [3]Department of Clinical Medicine and Therapeutics, Faculty of Health Sciences, University of Nairobi, Kenya.

References

1. Dye C, Scheele S, Dolin P, et al. Global burden of tuberculosis. JAMA: the journal of the American Medical Association. 1999;282:677–86.
2. Dye C, Scheele S, Dolin P, et al. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. Jama. 1999;282(7):677-86.
3. World Health Organisation. Global Tuberculosis Report. 2020. https://www.who.int/publications/i/item/9789240013131 (accessed 13 July 2022).
4. World Health Organization. Global tuberculosis report. Geneva; 2021. https://www.who.int/publications/i/item/9789240037021 (accessed 13 July 2022).
5. Ford N, Matteelli A, Shubber Z, et al. TB as a cause of hospitalization and in-hospital mortality among people living with HIV worldwide: a systematic review and meta-analysis. Journal of the International AIDS Society. 2016;19(1):20714.
6. Ai JW, Ruan QL, Liu QH, et al. Updates on the risk factors for latent tuberculosis reactivation and their managements. Emerg Microbes Infect. 2016;5(2):e10.
7. Vynnycky E, Fine PE. The natural history of tuberculosis: the implications of age-dependent risks of disease and the role of reinfection. Epidemiology and infection. 1997;119(2):183-201.
8. Houben RMGJ, Dodd PJ. The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling. PLOS Medicine. 2016;13(10):e1002152.
9. Cohen A, Mathiasen VD, Schön T, et al. The global prevalence of latent tuberculosis: a systematic review and meta-analysis. Eur Respir J. 2019;54(3).
10. Basera TJ, Ncayiyana J, Engel ME. Prevalence and risk factors of latent tuberculosis infection in Africa: a systematic review and meta-analysis protocol. BMJ Open. 2017;7(7):e012636.
11. González-Moreno J, García-Gasalla M, Losada-López I, et al. IGRA testing in patients with immune-mediated inflammatory diseases: which factors influence the results? Rheumatol Int. 2018;38(2):267-73.
12. Ncayiyana JR, Bassett J, West N, et al. Prevalence of latent tuberculosis infection and predictive factors in an urban informal settlement in Johannesburg, South Africa: a cross-sectional study. BMC Infectious Diseases. 2016;16(1):661.
13. Santos JA, Duarte R, Nunes C. Host factors associated to false negative and indeterminate results in an interferon-γ release assay in patients with active tuberculosis. Pulmonology. 2020;26(6):353-62.
14. Antonucci G, Girardi E, Raviglione MC, et al. Risk Factors for Tuberculosis in HIV-lnfected Persons: A Prospective Cohort Study. Jama. 1995;274(2):143-8.
15. Akolo C, Adetifa I, Shepperd S, et al. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database of Systematic Reviews. 2010(1).
16. World Health Organisation. Consolidated guidelines on tuberculosis. Module 1: prevention – tuberculosis preventive treatment. Geneva: World Health Organization; 2020. https://www.who.int/publications/i/item/9789240001503(accessed 13 July 2022).
17. Jensen AV, Jensen L, Faurholt-Jepsen D, et al. The prevalence of latent mycobacterium tuberculosis infection based on an interferon-γ release assay: a cross-sectional survey among urban adults in Mwanza, Tanzania. PloS one. 2013;8(5):e64008.
18. Kaplan SR, Escudero JN, Mecha J, et al. Interferon gamma release assay and tuberculin skin test performance in pregnant women living with and without HIV. J Acquired Immune Deficiency Syndromes. 2022;89(1):98-107.
19. Aladesanmi AO, Ojuawo OB, Aladesanmi OO, et al. Diagnosis of latent tuberculosis among HIV infected patients in Ilorin, Nigeria using tuberculin skin test and interferon gamma release assay. Pan Afr Med J. 2021;38:24.
20. World Health Organisation. Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. 2018 [updated 2018. https://apps.who.int/iris/handle/10665/260233.
21. Oliveira S, Trajman A, Paniago AMM, et al. Frequency of indeterminate results from an interferon-gamma release assay among HIV-infected individuals. J Bras Pneumol. 2017;43(3):215-8.

22. Oni T, Gideon HP, Bangani N, et al. Risk factors associated with indeterminate gamma interferon responses in the assessment of latent tuberculosis infection in a high-incidence environment. Clinical and vaccine immunology : CVI. 2012;19(8):1243-7.
23. Luetkemeyer AF, Charlebois ED, Flores LL, et al. Comparison of an interferon-gamma release assay with tuberculin skin testing in HIV-infected individuals. Am J Respir Crit Care Med. 2007;175(7):737-42.
24. Jeong SJ, Han SH, Kim CO, et al. Predictive factors for indeterminate result on the QuantiFERON test in an intermediate tuberculosis-burden country. Journal of Infection. 2011;62(5):347-54.
25. Darby J, Black J, Buising K. Interferon-gamma release assays and the diagnosis of tuberculosis: have they found their place? Internal Medicine Journal. 2014;44(7):624-32.
26. Papay P, Eser A, Winkler S, et al. Predictors of indeterminate IFN-γ release assay in screening for latent TB in inflammatory bowel diseases. Eur J Clin Invest. 2011;41(10):1071-6.
27. Bhosale R, Alexander M, Deshpande P, et al. Stages of pregnancy and HIV affect diagnosis of tuberculosis infection and Mycobacterium tuberculosis (MTB)-induced immune response: Findings from PRACHITi, a cohort study in Pune, India. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. 2021;112:205-11.
28. Kroon EE, Kinnear CJ, Orlova M, et al. An observational study identifying highly tuberculosis-exposed, HIV-1-positive but persistently TB, tuberculin and IGRA negative persons with M. tuberculosis specific antibodies in Cape Town, South Africa. EBioMedicine. 2020;61:103053.
29. Lawn SD, Bekker LG, Wood R. How effectively does HAART restore immune responses to Mycobacterium tuberculosis? Implications for tuberculosis control. AIDS (London, England). 2005;19(11):1113-24.
30. Brock I, Ruhwald M, Lundgren B, et al. Latent tuberculosis in HIV positive, diagnosed by the M. tuberculosis specific interferon-gamma test. Respir Res. 2006;7(1):56.
31. Raby E, Moyo M, Devendra A, et al. The effects of HIV on the sensitivity of a whole blood IFN-gamma release assay in Zambian adults with active tuberculosis. PloS one. 2008;3(6):e2489.
32. Le T, Wright EJ, Smith DM, et al. Enhanced CD4+ T-cell recovery with earlier HIV-1 antiretroviral therapy. N Engl J Med. 2013;368(3):218-30.
33. Kufa T, Shubber Z, MacLeod W, et al. CD4 count recovery and associated factors among individuals enrolled in the South African antiretroviral therapy programme: an analysis of national laboratory based data. PloS One. 2019;14(5):e0217742.
34. Fisk TL, Hon HM, Lennox JL, et al. Detection of latent tuberculosis among HIV-infected patients after initiation of highly active antiretroviral therapy. AIDS (London, England). 2003;17(7):1102-4.
35. Bishop J, DeShields S, Cunningham T, et al. CD4 count recovery after antiretroviral therapy initiation in patients infected with the human immunodeficiency virus. Am J of the Med Sci. 2016;352.
36. Badawi A, Liu CJ. Obesity and prevalence of latent tuberculosis: a population-based survey. Infect Dis. 2021;14:1178633721994607.
37. Critchley JA, Restrepo BI, Ronacher K, et al. Defining a research agenda to address the converging epidemics of tuberculosis and diabetes: Part 1: epidemiology and clinical management. Chest. 2017;152(1):165-73.
38. Roth J, Sahota N, Patel P, et al. Obesity paradox, obesity orthodox, and the metabolic syndrome: an approach to unity. Mol Med. 2017;22:873-85.
39. Barron MM, Shaw KM, Bullard KM, et al. Diabetes is associated with increased prevalence of latent tuberculosis infection: findings from the National Health and Nutrition Examination Survey, 2011-2012. Diabetes Res Clin Pract. 2018;139:366-79.
40. Badawi A, Sayegh S, Sallam M, et al. The global relationship between the prevalence of diabetes mellitus and incidence of tuberculosis: 2000-2012. Glob J Health Sci. 2014;7(2):183-91.

41. Puryear SB, Fatch R, Beesiga B, et al. Higher levels of alcohol use are associated with latent tuberculosis infection in adults living with human immunodeficiency virus. Clin Infect dis. 2021;72(5):865-8.
42. Imtiaz S, Shield KD, Roerecke M. Alcohol consumption as a risk factor for tuberculosis: meta-analyses and burden of disease. Eur Respir J. 2017;50(1).
43. Rehm J, Samokhvalov AV, Neuman MG, et al. The association between alcohol use, alcohol use disorders and tuberculosis (TB). A systematic review. BMC Public Health. 2009;9:450.
44. Lin W-C, Lin H-H, Lee SS-J, et al. prevalence of latent tuberculosis infection in persons with and without human immunodeficiency virus infection using two interferon-gamma release assays and tuberculin skin test in a low human immunodeficiency virus prevalence, intermediate tuberculosis-burden country. J Microbiol, Immunol Infect. 2016;49(5):729-36.
45. Kizza FN, List J, Nkwata AK, et al. prevalence of latent tuberculosis infection and associated risk factors in an urban African setting. BMC Infect Dis. 2015;15:165.